OncoMatch/Clinical Trials/NCT06536959
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
Is NCT06536959 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine for relapsed acute myeloid leukemia.
Treatment: PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine — The efficiency and safety of PD-1 inhibitor in combination with venetoclax and hypomethylation agent in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome remain uncertain. In this study, the investigators aimed to assess safety and response to a new PD-1 inhibitor-based triple-drug combination regimen (venetoclax + hypomethylation agent + PD-1 inhibitor) in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome patients, or who had positive minimal residual disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Performance status
ECOG 0–3(Limited self-care)
Demographics
Prior therapy
Must have received: induction chemotherapy
Patients who did not respond or had disease recurrence after 1 course of induction chemotherapy or had positive immune residues after induction chemotherapy or positive molecular residues (if any) after induction chemotherapy
Cannot have received: major surgery
Major surgery...within 2 weeks of the first medication
Cannot have received: radiotherapy
radiotherapy...within 2 weeks of the first medication
Cannot have received: chemotherapy
chemotherapy...within 2 weeks of the first medication
Cannot have received: biological therapy
biological therapy...within 2 weeks of the first medication
Cannot have received: immunotherapy
immunotherapy...within 2 weeks of the first medication
Cannot have received: experimental therapy
experimental therapy...within 2 weeks of the first medication
Lab requirements
Kidney function
creatinine≤2×uln
Liver function
alt and ast ≤2×uln; bilirubin≤2×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06536959 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior major surgery, radiotherapy, chemotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify